COVID-19 prevention and health promotion for the whole community DOI Open Access
Mohammed Mahmood Mohammed,

A. Y. Umar

Journal of Public Health and Diseases, Journal Year: 2023, Volume and Issue: 6(2), P. 31 - 38

Published: Dec. 30, 2023

As our understanding of Covid-19 has grown, numerous techniques for preventing its spread have emerged. Scholars and practitioners in public health focused on four important prevention strategies: behavioural, technical, biomedical, structural/community-level interventions. Recent material these areas provides an overview current preventive breakthroughs. Current COVID-19 models, which build traditional techniques, use intimate partners, families, social media, emerging technology, prescription therapy, immunization, regulatory changes to influence change. Despite significant success, more action is required meet the national goal stopping epidemic. Government non-governmental organizations are uniquely positioned promote science collaboration with cross-disciplinary professionals from other domains.

Language: Английский

Probing the Structural Elements of Polysaccharide Adjuvants for Enhancing Respiratory Mucosal Response: From Surmounting Multi-Obstacles to Eliciting Cascade Immunity DOI
Zhixiang Cui, Hezhi Wang, Qin Lu

et al.

ACS Nano, Journal Year: 2025, Volume and Issue: unknown

Published: March 10, 2025

The immunomodulatory effects and excellent tolerability of polysaccharides make them optimal candidates for pulmonary vaccine adjuvants. Yet, the structure-immunostimulatory activity relationship remains unrevealed. Here, we developed nanovaccines decorated with four distinct structures─hyaluronic acid (HA), pectin (PC), chondroitin sulfate (SC), heparan (SH)─all sharing similar particle sizes zeta potential. Polysaccharides containing groups (SC, SH) exhibited superior efficacy in overcoming natural inhalation barriers recruiting dendritic cells (DC). DC stimulation assays revealed that HA SH significantly upregulated expression costimulation signals, IL-6 secretion rising over 8.7-fold compared to pure OVA. Fluorescence resonance energy transfer demonstrated their detachment within lysosomal microenvironment, thereby enhancing antigen cross-presentation. However, vivo findings only showed CCR7 chemokine swiftly migrated lymph nodes. Molecular docking Western blot analyses further elucidated involvement TLR─MyD88─TRAF6─NF-κB/MAPK/IRF-7 signaling pathways. Notably, SH-modified induced a more robust cellular humoral immune response potential memory. This study confirms enhance activation combining acetyl offers promising adjuvant configuration augmenting mucosal, cellular, immunity.

Language: Английский

Citations

1
Inhalable hybrid nanovaccines with virus-biomimetic structure boost protective immune responses against SARS-CoV-2 variants DOI Creative Commons
Shuqi Wang,

Peiyang Ding,

Lingli Shen

et al.

Journal of Nanobiotechnology, Journal Year: 2024, Volume and Issue: 22(1)

Published: Feb. 27, 2024

Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), with different antigenic variants, has posed a significant threat to public health. It is urgent develop inhalable vaccines, instead of injectable elicit mucosal immunity against viral infections. Methods We reported an hybrid nanovaccine (NV RBD -MLipo) boost protective SARS-CoV-2 infection. Nanovesicles derived from genetically engineered 293T cells expressing ) were fused pulmonary surfactant (PS)-biomimetic liposomes containing MPLA (MLipo) yield NV -MLipo, which possessed virus-biomimetic structure, inherited expression and versatile properties. Results In contrast subcutaneous vaccination, via could efficiently enter the alveolar macrophages (AMs) AMs activation through MPLA-activated TLR4/NF-κB signaling pathway. Moreover, -MLipo induced T B activation, high level RBD-specific IgG secretory IgA (sIgA), thus elevating systemic immune responses, while reducing side effects. also demonstrated broad-spectrum neutralization activity (WT, Delta, Omicron) pseudovirus, protected immunized mice WT pseudovirus Conclusions This as effective safe nanovaccine, holds huge potential provoke robust immunity, might be promising vaccine candidate combat infectious diseases, including COVID-19 influenza.

Language: Английский

Citations

8
Induction of protective immune responses at respiratory mucosal sites DOI Creative Commons
Seok‐Chan Park,

Matthew J. Wiest,

Vivian Yan

et al.

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: July 2, 2024

Many pathogens enter the host through mucosal sites. Thus, interfering with pathogen entry local neutralization at sites therefore is an effective strategy for preventing disease. Mucosally administered vaccines have potential to induce protective immune responses This manuscript delves into some of latest developments in vaccination, particularly focusing on advancements adjuvant technologies and role these adjuvants enhancing vaccine efficacy against respiratory pathogens. It highlights anatomical immunological complexities system, emphasizing significance secretory IgA tissue-resident memory T cells responses. We further discuss differences between induced traditional parenteral vaccination approaches vs. administration strategies, explore advantages offered by immunization routes.

Language: Английский

Citations

7
Pathogen delivery route impacts disease severity in experimental Mycoplasma ovipneumoniae infection of domestic lambs DOI Creative Commons
Bryan Tegner Jacobson,

Jessica DeWit-Dibbert,

LaShae Zanca

et al.

Veterinary Research, Journal Year: 2025, Volume and Issue: 56(1)

Published: Jan. 13, 2025

Abstract M. ovipneumoniae is a respiratory pathogen that can cause mild to moderate pneumonia and reduced productivity in domestic lambs. However, studies on both natural experimental infection have reported highly variable clinical signs pathology. Here, we assessed the impact of administering upper tract (URT) or lower (LRT) two-month-old specific pathogen-free Lambs were inoculated with PBS (control) ceftiofur-treated nasal wash fluid obtained from sheep infection, monitored for eight weeks, subsequently euthanized. All lambs URT LRT groups developed stable . led weight gains disease, significantly greater effects following inoculation compared inoculation. At necropsy, via showed consolidation cranial lung lobes. In addition, histological alveolar, bronchiolar, interstitial inflammation more severe group. loads trachea bronchi also higher after than Interestingly, 9/10 tested positive haemolytica swab but not bronchial samples. summary, our study suggests bypassing protective mechanisms by delivering pathogens leads disease damage delivery URT.

Language: Английский

Citations

0
Mucosal immunotherapy targeting APC in lung disease DOI Creative Commons
Yangqi Liu, Zijian Chen, Hong‐Lin Cheng

et al.

Journal of Inflammation, Journal Year: 2025, Volume and Issue: 22(1)

Published: April 14, 2025

Several studies have demonstrated that the pulmonary immune response is primarily facilitated by antigen-presenting cells (APCs), and both professional non-professional APCs contribute to overall immunity. play unique roles mechanisms in pathogen elimination immunomodulation. Mucosal immunity exhibits potential advantages over traditional parenteral it stimulates defenses mucosal systemic tissues, which important for reducing burden of lung disease. However, obtaining a comprehensive understanding crosstalk between APC context various diseases remains challenging. This mini-review aimed elucidate novel immunity, targeting action during infections, allergies, malignant tumorigenesis. minreview provides insights into more effective therapeutic approaches diseases.

Language: Английский

Citations

0
Development of de-novo coronavirus 3-chymotrypsin-like protease (3CLpro) inhibitors since COVID-19 outbreak: A strategy to tackle challenges of persistent virus infection DOI
Lei Tian, Taotao Qiang,

Xiuding Yang

et al.

European Journal of Medicinal Chemistry, Journal Year: 2023, Volume and Issue: 264, P. 115979 - 115979

Published: Nov. 25, 2023

Language: Английский

Citations

10
A multi-epitope/CXCL11 prime/pull coronavirus mucosal vaccine boosts the frequency and the function of lung-resident memory CD4 + and CD8 + T cells and enhanced protection against COVID-19-like symptoms and death caused by SARS-CoV-2 infection DOI
Latifa Zayou, Swayam Prakash, Nisha R. Dhanushkodi

et al.

Journal of Virology, Journal Year: 2023, Volume and Issue: 97(12)

Published: Dec. 1, 2023

Although the current rate of SARS-CoV-2 infections has decreased significantly, COVID-19 still ranks very high as a cause death worldwide. As October 2023, weekly mortality is at 600 deaths in United States alone, which surpasses even worst rates recorded for influenza. Thus, long-term outlook serious concern outlining need next-generation vaccine. This study found that prime/pull coronavirus vaccine strategy increased frequency functional SARS-CoV-2-specific CD4

Language: Английский

Citations

10
Prevention of incident SARS-CoV-2 infection through combined intranasal and intradermal administration of the GLS-5310 DNA vaccine during the Omicron outbreak DOI
Joel N. Maslow,

Javier O Morales-Ramirez,

Christine C. Roberts

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: May 5, 2025

Abstract We evaluated the safety and immunogenicity of boost vaccination with GLS-5310 SARS-CoV-2 DNA vaccine to those previously vaccinated Ad26.S.CoV2, BNT162b2, or mRNA-1273 vaccines. was administered intradermally (ID) followed by application suction using GeneDerm device, ID as well intranasally (IN) nasal atomizer. tolerated. With respect primary type, induced a 1.5- 4-fold increase in antibody titers, up 14.4-fold T cell responses ELISpot. Incident infections, during period Omicron prevalence, were reported for 24.2% participants: 1 17 (5.9%) plus IN versus 16 53 (30.2%) only, p = 0.042 (chi-square analysis). This first ever trial showed potential protection against incident infection. NCT Clinical Trial number: NCT05182567

Language: Английский

Citations

0
New insights for the development of efficient DNA vaccines DOI Creative Commons
Simone Berger, Yanira Zeyn, Ernst Wagner

et al.

Microbial Biotechnology, Journal Year: 2024, Volume and Issue: 17(11)

Published: Nov. 1, 2024

Abstract Despite the great potential of DNA vaccines for a broad range applications, ranging from prevention infections, over treatment autoimmune and allergic diseases to cancer immunotherapies, implementation such therapies clinical is far behind expectations up now. The main reason poor immunogenicity in humans. Consequently, improvement performance vivo required. This mini‐review provides an overview current state various strategies enhance immunogenic vaccines, including (i) optimization construct itself regarding size, nuclear transfer transcriptional regulation; (ii) use appropriate adjuvants; (iii) improved delivery, example, by careful choice administration route, physical methods as electroporation nanomaterials that may allow cell type‐specific targeting. Moreover, combining nanoformulated with other immunotherapies prime‐boost help success treatment.

Language: Английский

Citations

2
Blended BA.5 infection within 8 days after a boosted bivalent mRNA vaccination strengthens and lengthens the host immunity DOI Creative Commons

Mingzhu Huang,

Tingting Cui, Siyi Liu

et al.

Journal of Medical Virology, Journal Year: 2024, Volume and Issue: 96(3)

Published: March 1, 2024

Abstract The impact of SARS‐CoV‐2 infection shortly after vaccination on vaccine‐induced immunity is unknown, which also one the concerns for some vaccinees during pandemic. Here, based a cohort individuals who encountered BA.5 within 8 days receiving fourth dose bivalent mRNA vaccine, preceded by three doses inactivated vaccines, we show that booster provided 48% protection efficacy against symptomatic infections. At Day 7 postvaccination, level neutralizing antibodies (Nabs) WT and strains in uninfected group trended higher than those group. Moreover, there were greater variations Nabs levels significant decrease virus‐specific CD4 + T cell response observed However, significantly increased Nab XBB.1.9.1 (symptomatic > asymptomatic group) at 10 resulted more gradual compared to 90. Our data suggest might hinder early generation recall but strengthens later phase. confirmed can enhance host regardless short interval between alleviate about infections vaccination, provides valuable guidance developing future vaccine administration strategies.

Language: Английский

Citations

1